ReShape Lifesciences Faces Stock Challenges Amid Market Pressures ReShape Lifesciences stock has hit a 52-week low of $0.61, reflecting a sharp decline from its previous high of $29. Market pressures, including reduced revenue and negative EBITDA, have impacted the company. Despite recent strategic moves, such as a merger and asset sales, investors remain cautious about its financial stability.5